Analyst Stock Recommendations For ReShape Lifesciences Inc. (RSLS), MGIC Investment Corporation (MTG)

ReShape Lifesciences Inc. (NASDAQ:RSLS) tinted gains of +0.54% (0 points) to US$0.76. The volume of 0.73 Million shares climbed down over an trading activity of 1.08 Million shares. EPS ratio determined by looking at last 12 month figures is -876.51. Over the same time span, the stock marked US$3756.9 as its best level and the lowest price reached was US$0.74. The corporation has a market cap of US$0.44 Million.

ReShape Lifesciences Inc. (NASDAQ:RSLS)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 32.8 percent. The return on equity ratio or ROE stands at -123.4 percent while most common profitability ratio return on investment (ROI) was -41.1 percent. The company’s institutional ownership is monitored at 5.3 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 13.9 percent gross margin.

MGIC Investment Corporation (NYSE:MTG) is worth US$4.06 Billion and has recently risen 0.54% to US$11.25. The latest exchange of 3.49 Million shares is above its average trading activity of 3.16 Million shares. The day began at US$10.99 but the price moved to US$10.8 at one point during the trading and finally capitulating to a session high of US$11.27. The stock tapped a 52-week high of US$16.21 while the mean 12-month price target for the shares is US$15.92.

Currently, the stock carries a price to earnings ratio of 6.44, a price to book ratio of 1.17, and a price to sales ratio of 3.66. For the past 5 years, the company’s revenue has grown -5%, while the company’s earnings per share has grown 17.9%. With an institutional ownership near 94.6%, it carries an earnings per share ratio of 1.75.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 4 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 1 analysts call it Underweight, while 5 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.